Rationale and necessity for delivery of RRx-001, a Myc and CD47 antagonist, by intravenous blood mix

RRx-001, a dinitroazetidine-based small molecule in Phase 3 for small cell lung cancer (SCLC) and in a randomized trial for the treatment of COVID-19, is a first-in-class Myc inhibitor that also do...